A new combination of three medications has completely cleared HIV infection in newborn primates, offering hope that infants born to mothers with HIV could be cured rather than face a lifetime of treatment. Scientists at Oregon Health & Science University tested antiretroviral therapy (ART), broadly neutralizing antibodies (bNAbs), and an experimental monoclonal antibody called leronlimab in eight infant rhesus macaques infected with a virus similar to HIV called simian-human immunodeficiency virus (SHIV). The triple therapy eliminated the virus entirely, while no individual or dual combination of the three treatments could fully stop the virus.

Why Is a Cure for Newborns With HIV So Difficult to Achieve?

The challenge of curing HIV in newborns became clear in 2013 when a baby girl known as the "Mississippi baby" made international headlines. She received antiretroviral therapy starting just 30 hours after birth and continued until 18 months old, with no detectable virus for over two years. However, when she was almost four years old, the HIV returned, forcing her back onto lifelong medication. This case shattered hopes that early intervention alone could provide a permanent cure.

The problem is that HIV establishes what researchers call a "viral reservoir" in the body, a hidden pool of infected cells that standard treatments cannot fully eliminate. Once this reservoir forms, the virus can rebound even after years of successful suppression. The window to prevent this from happening is extremely narrow, making timing critical in newborns who are exposed to the virus during delivery.

How Does the Triple-Drug Approach Work Differently?

The three medications in this combination attack HIV through distinct mechanisms, leaving the virus with nowhere to hide. Here's how each component contributes to viral clearance:

• Antiretroviral Therapy (ART): This standard HIV treatment essentially turns off the "faucet" by blocking the virus's ability to replicate, though it still allows a small amount of virus to continue spreading to other cells.
• Broadly Neutralizing Antibodies (bNAbs): These immune proteins neutralize the virus directly and block it from infecting new cells, preventing the spread that ART alone cannot fully contain.
• Leronlimab (Monoclonal Antibody): This experimental drug blocks the CCR5 protein on CD4+ immune cells, which is the surface receptor that HIV uses to attach and enter cells, providing a third barrier to infection.

"Each of the three drugs has a different way of corralling the virus, and it simply has nowhere to go," said Nancy Haigwood, lead researcher at the Oregon National Primate Research Center at Oregon Health & Science University.

Nancy Haigwood, Lead Researcher, Oregon National Primate Research Center at Oregon Health & Science University

The strength of this approach lies in its redundancy. If the virus develops resistance to one medication, the other two continue to block infection through different pathways. This multi-pronged strategy proved so effective in the primate study that researchers found no evidence of virus in any tissues of the treated animals.

What Do the Study Results Actually Show?

The research, published in Nature Microbiology, compared the triple therapy to untreated controls and to animals receiving only one or two of the medications. The results were striking: untreated infant macaques progressed rapidly to disease, while those receiving incomplete combinations could not fully suppress the virus. Only the full triple therapy achieved complete viral clearance.

An important finding was that the animals treated with the triple therapy did not mount a strong immune response against the treatment itself, which suggests the approach is well-tolerated. This is significant because it means the therapy could potentially be repeated if needed without triggering harmful immune reactions.

"The evidence for viral clearance is very strong, and animals did not mount an immune response, further supporting clearance," emphasized Nancy Haigwood.

Nancy Haigwood, Lead Researcher, Oregon National Primate Research Center at Oregon Health & Science University

When Could This Treatment Be Tested in Human Infants?

The timeline for human clinical trials could move relatively quickly because all three components of the triple therapy have already been extensively tested individually in humans. Researchers are optimistic about moving forward, though they acknowledge the importance of rigorous clinical testing before declaring success.

One key question researchers need to answer is whether the treatment window extends beyond the 72 hours after viral exposure that was used in the primate study. If human newborns have a slower initial spread of the virus, there may be more time to administer the triple therapy before the viral reservoir becomes established. Understanding this window of opportunity will be crucial for practical implementation in clinical settings.

"This work further supports the idea for intervention in babies as close to birth as possible, and it could mean that children no longer must take drugs for their entire lives," stated Nancy Haigwood.

Nancy Haigwood, Lead Researcher, Oregon National Primate Research Center at Oregon Health & Science University

Could This Approach Work Beyond Newborns?

While the current research focuses on newborns exposed to HIV during delivery, researchers believe the triple therapy could potentially be adapted for newly infected adults as well. However, treating adults presents a different challenge: we typically don't know the exact moment of exposure, making it harder to intervene within the critical window before the viral reservoir forms.

Geographic and economic barriers also complicate broader application. Access to these biologic medications remains limited in parts of the world with fewer healthcare resources, a reality that researchers acknowledge must be addressed for this breakthrough to benefit all children at risk of HIV infection.

The discovery represents a significant shift in how scientists think about HIV infection. Rather than viewing the virus as something that must be managed indefinitely, this research demonstrates that with the right combination of drugs administered at the right time, HIV could potentially be eliminated entirely before it establishes the persistent infection that makes current treatment so challenging.